Areteia Therapeutics

CHAPEL HILL, NC · Founded 2022 · Biotech · Defunct

Clinical-stage therapeutic candidates (now defunct)

Claim this profile

Follows are private to you and power your alerts

Updated · areteiatx.com

Sector
Biotech
Headquarters
CHAPEL HILL, NC
Founded
2022
Latest Form D
$175M, Jul 2022
Total capital
$175M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$175M
1 Form D · last Jul 2022
51 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
19 pending · first 2023
Rank in peer group#397 of 1449

Capital timeline

2022FEDERAL ↑EQUITY ↓Cumulative $175M1st Form D$175M
2022FEDERAL ↑EQUITY ↓Cumulative $175M1st Form D$175M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$175M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Michael E. BozikResearcherDirectorLinked by 2 patents
  • Adam KoppelDirectorNamed in SEC Form D filings
  • Benjamin GomezDirectorNamed in SEC Form D filings
  • Christopher E. CourtsExecutive OfficerNamed in SEC Form D filings
  • Christopher Todd CoxExecutive OfficerNamed in SEC Form D filings
  • Chris E. VisioliExecutive OfficerNamed in SEC Form D filings
Show all 14 people
  • Daniel E. BeckerDirectorNamed in SEC Form D filings
  • Elyse E. StockDirectorNamed in SEC Form D filings
  • Ian ReadDirectorNamed in SEC Form D filings
  • Jorge E. BartolomeExecutive Officer, DirectorNamed in SEC Form D filings
  • Paul BernsDirectorNamed in SEC Form D filings
  • Robin E. WalkerExecutive OfficerNamed in SEC Form D filings
  • Stephen E. ButtsDirectorNamed in SEC Form D filings
  • Whit E. BernardExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 21
  • PendingUse Of Dexpramipexole For The Treatment Of Moderate To Severe AsthmaUSPTOApplication 19340207
  • PendingUse Of Dexpramipexole For The Treatment Of Eosinophilic CopdUSPTOApplication 19211099
  • PendingOsmotic Tablets Of Dexpramipexole And Methods Of Manufacturing And Use ThereofUSPTOApplication 18990646
Show all 21 patent records
  • Use Of Dexpramipexole For The Treatment Of Moderate To Severe AsthmaJan 22, 2026 · Application 19340207Pending
  • Use Of Dexpramipexole For The Treatment Of Eosinophilic CopdNov 20, 2025 · Application 19211099Pending
  • Osmotic Tablets Of Dexpramipexole And Methods Of Manufacturing And Use ThereofJul 3, 2025 · Application 18990646Pending
  • Use Of Dexpramipexole For The Treatment Of Inadequately Controlled Moderate To Severe AsthmaJun 26, 2025 · Application 18988479Pending
  • Matrix Tablets Of Dexpramipexole And Methods Of Manufacturing And Use ThereofJun 26, 2025 · Application 18990723Pending
  • Compositions And Methods For Treating Conditions Related To Elevated Levels Of Eosinophils And/or BasophilsMar 27, 2025 · Application 18905816Pending
  • Compositions And Methods For Treating Conditions Related To Elevated Levels Of Eosinophils And/or BasophilsNov 12, 2024 · US 12,138,249Granted
  • Use Of Dexpramipexole For The Treatment Of Moderate To Severe AsthmaFeb 8, 2024 · Application 18485086Pending
  • Use Of Dexpramipexole For The Treatment Of Moderate To Severe AsthmaFeb 8, 2024 · Application 18485082Pending
  • Compositions And Methods For Treating Conditions Related To Elevated Levels Of Eosinophils And/or BasophilsMar 28, 2023 · US 11,612,589Granted
  • Use Of Dexpramipexole For The Treatment Of Moderate To Severe AsthmaFeb 10, 2022 · Application 17395059Pending
  • Pharmaceutical Composition Of Dexpramipexole And Methods Of Manufacturing And Use ThereofApplication 63706522Pending
  • Use Of Dexpramipexole For The Treatment Of Eosinophilic CopdApplication 63648963Pending
  • Pharmaceutical Composition Of Dexpramipexole And Methods Of Manufacturing And Use ThereofApplication 63612916Pending
  • Use Of Dexpramipexole For The Treatment Of Inadequately Controlled Moderate To Severe AsthmaApplication 63612850Pending
  • Pharmaceutical Composition Of Dexpramipexole And Methods Of Manufacturing And Use ThereofApplication 63612893Pending
  • Use Of Dexpramipexole For The Treatment Of Inadequately Controlled Moderate To Severe AsthmaApplication PCTUS2024060962Pending
  • Matrix Tablets Of Dexpramipexole And Methods Of Manufacturing And Use ThereofApplication PCTUS2024061362Pending
  • Osmotic Tablets Of Dexpramipexole And Methods Of Manufacturing And Use ThereofApplication PCTUS2024061368Pending
  • Pharmaceutical Composition Of Dexpramipexole And Methods Of Manufacturing And Use ThereofApplication 63706524Pending
  • Use Of Dexpramipexole For The Treatment Of Eosinophilic CopdApplication PCTUS2025029881Pending
  • GondolaBioSimilar federal contract value in Biotech · null in contracts
  • BIOHARVEST SCIENCES INC.Similar federal contract value in Biotech · null in contracts
  • Celcuity Inc.Similar federal contract value in Biotech · null in contracts
  • TRIANA BiomedicinesSimilar federal contract value in Biotech · null in contracts
  • Monocacy Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
  • Fulcrum TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .